Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in ...

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast ...

Olympic great described this year's star-studded cancer-research concert as his most “epic" yet. The benefit promises to ...

1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...

The Constitution State leads in its five-year survival rate and high-risk screening rate, the American Lung Association said.

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the ...

Breast cancer is commonly portrayed as challenging yet curable: A lump is discovered, then through some combination of ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in ...